Dendritic cell–tumor cell hybrids and immunotherapy: what's next?

References

• Bonnotte B, Favre N, Moutet M, Fromentin A, Solary E, Martin M, . Bcl-2-mediated inhibition of apoptosis prevents immunogenicity and restores tumorigenicity of spontaneously regressive tumors. J Immunol. 1998;161:1433–8.
   PubMed Web of Science ®Google Scholar
• Bonnotte B, Favre N, Moutet M, Fromentin A, Solary E, Martin M, . Role of tumor cell apoptosis in tumor antigen migration to the draining lymph nodes. J Immunol. 2000;164:1995–2000.
   PubMed Web of Science ®Google Scholar
• Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J, . Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol. 2000;165:3797–803.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–52.
   PubMed Web of Science ®Google Scholar
• Bonnotte B, Larmonier N, Favre N, Fromentin A, Moutet M, Martin M, . Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J Immunol. 2001;167:5077–83.
   PubMed Web of Science ®Google Scholar
• Alli R, Savithri B, Das S, Varalakshmi C, Rangaraj N, Khar A. Involvement of NKR-P2/NKG2D in DC-mediated killing of tumor targets: indicative of a common, innate, target-recognition paradigm? Eur J Immunol. 2004;34: 1119–26.
   Google Scholar
• Lynch DH. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev. 2008;222:277–86.
   PubMed Web of Science ®Google Scholar
• Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9:271–85.
   PubMed Web of Science ®Google Scholar
• Watts TH. TNF/TNFR family members in costimulation of T cell responses. Ann Rev Immunol. 2005;23:23–68.
   PubMed Web of Science ®Google Scholar
• Couderc B, Zitvogel L, Douin-Echinard V, Djennane L, Tahara H, Favre G, . Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther. 1998;5:163–75.
   PubMed Web of Science ®Google Scholar
• Lorenz MG, Kantor JA, Schlom J, Hodge JW. Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L). Hum Gene Ther. 1999;10:1095–103.
   PubMed Web of Science ®Google Scholar
• Nieland JD, Graus YF, Dortmans YE, Kremers BL, Kruisbeek AM. CD40 and CD70 co-stimulate a potent in vivo antitumor T cell response. J Immunother. 1998;21:225–36.
   PubMed Web of Science ®Google Scholar
• Liu X, Bai X-F, Wen J, Gao J-X, Liu J, Lu P, . B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8 + T lymphocytes in vivo. J Exp Med. 2001;194:1339–48.
   PubMed Web of Science ®Google Scholar
• Wallin JJ, Liang L, Bakardjiev A, Sha WC. Enhancement of CD8+ T cell responses by ICOS/B7h costimulation. J Immunol. 2001;167:132–9.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Diab A, Perales M-A, Wolchok JD, Rizzuto G, Merghoub T, . Agonist anti-GITR antibody enhances vaccine-induced CD8+ T-cell responses and tumor immunity. Cancer Res. 2006;66:4904–12.
   PubMed Web of Science ®Google Scholar
• Zhou P, L'Italien L, Hodges D, Schebye XM. Pivotal roles of CD4+ effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J Immunol. 2007;179:7365–75.
   PubMed Web of Science ®Google Scholar
• Chaux P, Favre N, Bonnotte B, Moutet M, Martin M, Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression. A role in the immune tolerance to antigenic tumors. Adv Exp Med Biol. 1997;417:525–8.
   PubMedGoogle Scholar
• Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, . Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4: 328–32.
   PubMed Web of Science ®Google Scholar
• Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, . Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother. 2006;55:819–29.
   PubMed Web of Science ®Google Scholar
• Soleimani A, Berntsen A, Svane IM, Pedersen AE. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scand J Immunol. 2009;70:481–9.
   PubMedGoogle Scholar
• Bettinotti M, Panelli MC, Ruppe E, Mocellin S, Phan GQ, White DE, Marincola FM. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170–178. Int J Cancer. 2003;105:210–6.
   PubMed Web of Science ®Google Scholar
• Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med. 1996;183:283–7.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood. 2002;100:174–7.
   PubMed Web of Science ®Google Scholar
• Hersey P, Menzies SW, Halliday GM, Nguyen T, Farrelly ML, DeSilva C, . Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother. 2004;53:125–34.
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, . Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995;1: 1297–302.
   PubMed Web of Science ®Google Scholar
• Nair SK, Hull S, Coleman D, Gilboa E, Lyerly HK, Morse MA. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer. 1999;82:121–4.
   PubMed Web of Science ®Google Scholar
• Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, . Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol. 2000;165:3492–6.
   PubMed Web of Science ®Google Scholar
• Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, . Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669–78.
   PubMed Web of Science ®Google Scholar
• Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, . Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA. 1995;92:8078–82.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Brocker EB, . Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17:563–70.
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, . Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte–macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003;21:4016–26.
   PubMed Web of Science ®Google Scholar
• Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, . Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer. 2000;86:385–92.
   PubMed Web of Science ®Google Scholar
• Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate. 1996;29:371–80.
   PubMed Web of Science ®Google Scholar
• Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA, . Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother (1997). 2000; 23:487–98.
   PubMed Web of Science ®Google Scholar
• Trepiakas R, Berntsen A, Hadrup SR, Bjørn J, Geertsen PF, Straten PT, . Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy. 2010;12:1–14.
   Google Scholar
• Boczkowski D, Nair SK, Nam J-H, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 2000;60: 1028–34.
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996;184:465–72.
   PubMed Web of Science ®Google Scholar
• Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res. 2001;61:3388–93.
   PubMed Web of Science ®Google Scholar
• Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, . Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol. 2001;166:2953–60.
   PubMed Web of Science ®Google Scholar
• Kyte JA, Kvalheim G, Lislerud K, Thor Straten P, Dueland S, Aamdal S, . T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol Immunother. 2007;56:659–75.
   PubMed Web of Science ®Google Scholar
• Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, . Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 2006;13:905–18.
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, . Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 2003;63:2127–33.
   PubMed Web of Science ®Google Scholar
• Sæbøe-Larssen S, Fossberg E, Gaudernack G. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods. 2002 Jan 1;259(1–2):191–203.
   Google Scholar
• Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, . Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol. 2005;174:3798–807.
   PubMed Web of Science ®Google Scholar
• Tuyaerts S, Michiels A, Corthals J, Bonehill A, Heirman C, Greef CD, . Induction of influenza matrix protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells. Cancer Gene Ther. 2003 Sep; 10(9):696–706.
   PubMed Web of Science ®Google Scholar
• Met Ö, Balslev E, Flyger H, Svane I. High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast Cancer Res Treat. 2011 Jan;125(2):395–406.
   Google Scholar
• Ueno H, Tcherepanova I, Reygrobellet O, Laughner E, Ventura C, Palucka AK, . Dendritic cell subsets generated from CD34+ hematopoietic progenitors can be transfected with mRNA and induce antigen-specific cytotoxic T cell responses*1. J Immunol Meth. 2004;285:171–80.
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, . Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001;98:49–56.
   PubMed Web of Science ®Google Scholar
• Mosca PJ, Lyerly HK, Clay TM, Morse MA, Lyerly HK. Dendritic cell vaccines. Front Biosci. 2007;12:4050–60.
   Google Scholar
• Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer. 2001;94:459–73.
   PubMed Web of Science ®Google Scholar
• Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, . Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science. 1994;263:518–20.
   PubMed Web of Science ®Google Scholar
• Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997;3:558–61.
   PubMed Web of Science ®Google Scholar
• Davidson RL, Gerald PS. Improved techniques for the induction of mammalian cell hybridization by polyethylene glycol. Somatic Cell Genet. 1976;2:165–76.
   PubMedGoogle Scholar
• Finaz C, Lefevre A, Teissie J. Electrofusion. A new, highly efficient technique for generating somatic cell hybrids. Exp Cell Res. 1984;150:477–82.
   Google Scholar
• Akasaki YKT, Homma S, Abe T, Kofe D, Ohno T. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother. 2001;24: 106–13.
   Web of Science ®Google Scholar
• Gottfried E, Krieg R, Eichelberg C, Andreesen R, Mackensen A, Krause SW. Characterization of cells prepared by dendritic cell-tumor cell fusion. Cancer Immun. 2002 Nov 7;2:15–26.
   PubMedGoogle Scholar
• Lindner M, Schirrmacher V. Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylene-glycol versus electro-fusion protocols. Eur J Clin Invest. 2002;32:207–17.
   PubMed Web of Science ®Google Scholar
• Orentas RJ, Schauer D, Bin Q, Johnson BD. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cellular Immunol. 2001;213:4–13.
   PubMed Web of Science ®Google Scholar
• Cao X, Zhang W, Wang J, Huang X, Hamada H, Chen W, . Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte–macrophage colony-stimulating factor genetically modified dendritic cells. Immunology. 1999;97:616–25.
   PubMed Web of Science ®Google Scholar
• Kawada M, Ikeda H, Takahashi T, Ishizu A, Ishikura H, Katoh H, . Vaccination of fusion cells of rat dendritic and carcinoma cells prevents tumor growth in vivo. Int J Cancer. 2003;105:520–6.
   PubMedGoogle Scholar
• Kim GY, Chae HJ, Kim KH, Yoon MS, Lee KS, Lee CM, . Dendritic cell-tumor fusion vaccine prevents tumor growth in vivo. Biosci Biotechnol Biochem. 2007 Jan;71(1):215–21.
   Google Scholar
• Lespagnard L, Mettens P, Verheyden AM, Tasiaux N, Thielemans K, van Meirvenne S, . Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer. 1998;76:250–8.
   PubMed Web of Science ®Google Scholar
• Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol. 1998;161:5516–24.
   PubMed Web of Science ®Google Scholar
• Zhang JK, Li J, Zhang J, Chen HB, Chen SB. Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo. World J Gastroenterol. 2003;9:479–84.
   PubMed Web of Science ®Google Scholar
• Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell–leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother. 2002;51:299–310.
   PubMed Web of Science ®Google Scholar
• Kokhaei P, Rezvany MR, Virving L, Choudhury A, Rabbani H, Osterborg A, . Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia. 2003;17:894–9.
   PubMed Web of Science ®Google Scholar
• Shimizu K, Kuriyama H, Kjaergaard J, Lee W, Tanaka H, Shu S. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother. 2004;27:265–72.
   PubMed Web of Science ®Google Scholar
• Yasuda T, Kamigaki T, Nakamura T, Imanishi T, Hayashi S, Kawasaki K, . Dendritic cell–tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells. Oncol Rep. 2006;16:1317–24.
   PubMed Web of Science ®Google Scholar
• Kao JY, Zhang M, Chen CM, Chen JJ. Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer. Immunol Lett. 2005;101:154–9.
   PubMed Web of Science ®Google Scholar
• Draube A, Beyer M, Schumer S, Thomas RK, Tresckow B, Koslowsky TC, . Efficient activation of autologous tumor-specific T cells: a simple coculture technique of autologous dendritic cells compared to established cell fusion strategies in primary human colorectal carcinoma. J Immunother (1997). 2007;30:359–69.
   Google Scholar
• Tanaka Y, Koido S, Ohana M, Liu C, Gong J. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells. J Immunol. 2005; 174:1274–80.
   PubMedGoogle Scholar
• Takagi Y, Kikuchi T, Niimura M, Ohno T. Anti-tumor effects of dendritic and tumor cell fusions are not dependent on expression of MHC class I and II by dendritic cells. Cancer Lett. 2004;213:49–55.
   PubMed Web of Science ®Google Scholar
• Xia J, Tanaka Y, Koido S, Liu C, Mukherjee P, Gendler SJ, . Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol. 2003;170:1980–6.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Koido S, Chen D, Gendler SJ, Kufe D, Gong J. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol. 2001;101:192–200.
   PubMed Web of Science ®Google Scholar
• Lee WT, Shimizu K, Kuriyama H, Tanaka H, Kjaergaard J, Shu S. Tumor-dendritic cell fusion as a basis for cancer immunotherapy. Otolaryngol Head Neck Surg. 2005;132:755–64.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Shimizu K, Hayashi T, Shu S. Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol. 2002;220:1–12.
   PubMed Web of Science ®Google Scholar
• Gong J, Apostolopoulos V, Chen D, Chen H, Koido S, Gendler SJ, . Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology. 2000;101:316–24.
   PubMed Web of Science ®Google Scholar
• Koido S, Tanaka Y, Chen D, Kufe D, Gong J. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J Immunol. 2002;168:2111–7.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang W, Chan T, Saxena A, Xiang J. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk Res. 2002;26:757–63.
   PubMed Web of Science ®Google Scholar
• Gong J, Koido S, Chen D, Tanaka Y, Huang L, Avigan D, . Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood. 2002;99:2512–7.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Tanaka H, Tanaka J, Wang R, Averbook BJ, Cohen PA, . Immunogenicity and therapeutic efficacy of dendritic–tumor hybrid cells generated by electrofusion. Clin Immunol. 2002;104:14–20.
   PubMed Web of Science ®Google Scholar
• Iinuma H, Okinaga K, Fukushima R, Inaba T, Iwasaki K, Okinaga A, . Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma. J Immunol. 2006;176:3461–9.
   PubMed Web of Science ®Google Scholar
• Zhang HM, Zhang LW, Liu WC, Cheng J, Si XM, Ren J. Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma. Cytotherapy. 2006;8:580–8.
   PubMed Web of Science ®Google Scholar
• Ko E, Luo W, Peng L, Wang X, Ferrone S. Mouse dendritic–endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity. Cancer Res. 2007;67:7875–84.
   PubMedGoogle Scholar
• Kjaergaard J, Wang LX, Kuriyama H, Shu S, Plautz GE. Active immunotherapy for advanced intracranial murine tumors by using dendritic cell–tumor cell fusion vaccines. J Neurosurg. 2005;103:156–64.
   PubMed Web of Science ®Google Scholar
• Takeda A, Homma S, Okamoto T, Kufe D, Ohno T. Immature dendritic cell/tumor cell fusions induce potent antitumour immunity. Eur J Clin Invest. 2003;33:897–904.
   PubMed Web of Science ®Google Scholar
• Du Y-C, Lin P, Zhang J, Lu Y-R, Ning Q-Z, Wang Q. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses. Tissue Antigens. 2006;67:368–76.
   Google Scholar
• Koido S, Hara E, Homma S, Torii A, Mitsunaga M, Yanagisawa S, . Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells. J Immunol. 2007;178:613–22.
   PubMedGoogle Scholar
• Kao JY, Gong Y, Chen CM, Zheng QD, Chen JJ. Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol. 2003;170:3806–11.
   PubMed Web of Science ®Google Scholar
• Ou X, Cai S, Liu P, Zeng J, He Y, Wu X, . Enhancement of dendritic cell–tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT. J Cancer Res Clin Oncol. 2008 May;134(5):525–33.
   Google Scholar
• Savai R, Schermuly RT, Pullamsetti SS, Schneider M, Greschus S, Ghofrani HA, . A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells. Cancer Res. 2007;67:5443–53.
   PubMedGoogle Scholar
• Savai R, Schermuly RT, Schneider M, Pullamsetti SS, Grimminger F, Seeger W, . Hybrid-primed lymphocytes and hybrid vaccination prevent tumor growth of Lewis lung carcinoma in mice. J Immunother. 2006;29:175–87.
   Google Scholar
• Alvarez E, Moga E, Barquinero J, Sierra J, Briones J. Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response. Gene Ther. 2010;17:469–77.
   Google Scholar
• Yasuda T, Kamigaki T, Kawasaki K, Nakamura T, Yamamoto M, Kanemitsu K, . Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol Immunother. 2007;56:1025–36.
   PubMed Web of Science ®Google Scholar
• Hu Z, Liu S, Mai X, Hu Z, Liu C. Anti-tumor effects of fusion vaccine prepared by renal cell carcinoma 786-O cell line and peripheral blood dendritic cells of healthy volunteers in vitro and in human immune reconstituted SCID mice. Cell Immunol. 2010;262:112–9.
   PubMed Web of Science ®Google Scholar
• Xu F, Ye Y-J, Liu W, Kong M, He Y, Wang S. Dendritic cell/tumor hybrids enhances therapeutic efficacy against colorectal cancer liver metastasis in SCID mice. Scand J Gastroenterol. 2010;45:707–13.
   PubMed Web of Science ®Google Scholar
• Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, . Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA. 2000;97:2715–8.
   PubMed Web of Science ®Google Scholar
• Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, . Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol. 2000;165:1705–11.
   PubMed Web of Science ®Google Scholar
• Scott-Taylor TH, Pettengell R, Clarke I, Stuhler G, La Barthe MC, Walden P, . Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta (BBA) Mol Basis Dis. 2000;1500:265–79.
   PubMed Web of Science ®Google Scholar
• Trevor KT, Cover C, Ruiz YW, Akporiaye ET, Hersh EM, Landais D, . Generation of dendritic cell–tumor cell hybrids by electrofusion for clinical vaccine application. Cancer Immunol Immunother. 2004 Aug;53(8):705–14.
   Google Scholar
• Jantscheff P, Spagnoli G, Zajac P, Rochlitz CF. Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells. Cancer Immunol Immunother. 2002;51:367–75.
   PubMed Web of Science ®Google Scholar
• Guo G, Chen S, Zhang J, Luo L, Yu J, Dong H, . Antitumor activity of a fusion of esophageal carcinoma cells with dendritic cells derived from cord blood. Vaccine. 2005;23: 5225–30.
   PubMed Web of Science ®Google Scholar
• Koido S, Hara E, Homma S, Namiki Y, Komita H, Takahara A, . Dendritic/pancreatic carcinoma fusions for clinical use: comparative functional analysis of healthy- versus patient-derived fusions. Clin Immunol. 2010;135:384–400.
   PubMed Web of Science ®Google Scholar
• Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sharav T, . Tumour–dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine. 2005;23: 2367–73.
   PubMed Web of Science ®Google Scholar
• Kugler ASG, Walden P, Zöller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, . Regression of human metastatic renal cell carcinoma after vaccination with tumor cell– dendritic cell hybrids. Nature Med. 2000;6:332–6.
   PubMed Web of Science ®Google Scholar
• Trefzer U, Weingart G, Chen Y, Herberth G, Adrian K, Winter H, . Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer. 2000;85:618–26.
   PubMed Web of Science ®Google Scholar
• Bostanci A, Vogel G. Research misconduct. German inquiry finds flaws, not fraud. Science. 2002;298:1531–3.
   Google Scholar
• Homma S, Matai K, Irie M, Ohno T, Kufe D, Toda G. Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinoma. J Gastroenterol. 2003; 38:989–94.
   PubMed Web of Science ®Google Scholar
• Homma S, Sagawa Y, Ito M, Ohno T, Toda G. Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin Exp Immunol. 2006;144:41–7.
   PubMed Web of Science ®Google Scholar
• Marten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, . Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther. 2003;14:483–94.
   PubMed Web of Science ®Google Scholar
• Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, . Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res. 2004;10:4699–708.
   PubMed Web of Science ®Google Scholar
• Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, . Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother (1997). 2007;30:749–61.
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother. 2001;50:337–44.
   PubMed Web of Science ®Google Scholar
• Barbuto JA, Ensina LF, Neves AR, Bergami-Santos P, Leite KR, Marques R, . Dendritic cell–tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother. 2004;53:1111–8.
   PubMed Web of Science ®Google Scholar
• Stuhler G, Walden P. Recruitment of helper T cells for induction of tumour rejection by cytolytic T lymphocytes. Cancer Immunol Immunother. 1994;39:342–5.
   PubMed Web of Science ®Google Scholar
• Mortarini R, Borri A, Tragni G, Bersani I, Vegetti C, Bajetta E, . Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+T cells in melanoma patients receiving interleukin 12. Cancer Res. 2000;60:3559–68.
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, . Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother (1997). 2004;27:452–9.
   PubMed Web of Science ®Google Scholar
• Wei Y, Sticca RP, Holmes LM, Burgin KE, Li J, Williamson J, . Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol. 2006;28:585–93.
   PubMed Web of Science ®Google Scholar
• Haenssle HA, Krause SW, Emmert S, Zutt M, Kretschmer L, Schmidberger H, . Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of a phase I/II study. J Immunother. 2004;27:147–55.
   PubMed Web of Science ®Google Scholar
• Queant S, Sarde CO, Gobert MG, Kadouche J, Roseto A. Antitumor response against myeloma cells by immunization with mouse syngenic dendritoma. Hybridoma (Larchmt). 2005;24:182–8.
   Google Scholar
• Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, . Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother. 2010;33:155–66.
   Google Scholar
• Ahmed A, Jevremovic D, Suzuki K, Kottke T, Thompson J, Emery S, . Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy. Gene Ther. 2003;10:1663–71.
   Google Scholar
• Bateman A, Bullough F, Murphy S, Emiliusen L, Lavillette D, Cosset FL, . Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res. 2000;60:1492–7.
   PubMed Web of Science ®Google Scholar
• Bateman AR, Harrington KJ, Kottke T, Ahmed A, Melcher AA, Gough MJ, . Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res. 2002;62:6566–78.
   PubMed Web of Science ®Google Scholar
• Diaz RM, Bateman A, Emiliusen L, Fielding A, Trono D, Russell SJ, . A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther. 2000;7: 1656–63.
   PubMed Web of Science ®Google Scholar
• Errington F, Bateman A, Kottke T, Thompson J, Harrington K, Merrick A, . Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. Clin Cancer Res. 2006;12:1333–41.
   PubMed Web of Science ®Google Scholar
• Errington F, Jones J, Merrick A, Bateman A, Harrington K, Gough M, . Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Ther. 2006;13:138–49.
   Google Scholar
• Gomez-Trevino A, Castel S, Lopez-Iglesias C, Cortadellas N, Comas-Riu J, Mercade E. Effects of adenovirus-mediated SV5 fusogenic glycoprotein expression on tumor cells. J Gene Med. 2003;5:483–92.
   Google Scholar
• Higuchi H, Bronk SF, Bateman A, Harrington K, Vile RG, Gores GJ. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy. Cancer Res. 2000;60:6396–402.
   PubMedGoogle Scholar
• Larmonier N, Merino D, Nicolas A, Cathelin D, Besson A, Bateman A, . Apoptotic, necrotic, or fused tumor cells: an equivalent source of antigen for dendritic cell loading. Apoptosis. 2006;11:1513–24.
   PubMed Web of Science ®Google Scholar
• Linardakis E, Bateman A, Phan V, Ahmed A, Gough M, Olivier K, . Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell–tumor cell fusion. Cancer Res. 2002;62:5495–504.
   PubMed Web of Science ®Google Scholar
• Zhang J, Frolov I, Russell SJ. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein. J Gene Med. 2004;6:1082–91.
   Google Scholar
• Phan V, Errington F, Cheong SC, Kottke T, Gough M, Altmann S, . A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat Med. 2003;9:1215–9.
   PubMedGoogle Scholar
• Cheong SC, Blangenois I, Franssen JD, Servais C, Phan V, Trakatelli M, Bruyns C, Vile R, Velu T, Brandenburger A. Generation of cell hybrids via a fusogenic cell line. J Gene Med. 2006;8:919–28.
   Google Scholar
• Morse MA, Clay TM, Mosca P, Lyerly HK. Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther. 2002;2:827–34.
   PubMed Web of Science ®Google Scholar
• Kalinski P, Okada H. Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Sem Immunol.22:173–82.
   Google Scholar
• Rosenberg SA, Sportes C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, . IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother. 2006;29:313–9.
   PubMed Web of Science ®Google Scholar
• Koido S, Tanaka Y, Tajiri H, Gong J. Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells. Vaccine. 2007;25:2610–9.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ma B, Zhou Y, Zhang M, Qiu X, Sui Y, . Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells. Breast Cancer Res Treat. 2007 Nov; 105(3):277–86.
   Google Scholar
• Neves AR, Ensina LF, Anselmo LB, Leite KR, Buzaid AC, Camara-Lopes LH, . Dendritic cells derived from metastatic cancer patients vaccinated with allogeneic dendritic cell–autologous tumor cell hybrids express more CD86 and induce higher levels of interferon-gamma in mixed lymphocyte reactions. Cancer Immunol Immunother. 2005 Jan;54(1):61–6.
   Google Scholar
• Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol. 2003;170:5317–25.
   PubMed Web of Science ®Google Scholar
• Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, . Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004;125:343–52.
   PubMed Web of Science ®Google Scholar
• Soruri A, Fayyazi A, Neumann C, Schlott T, Jung T, Matthes C, . Ex vivo generation of human anti-melanoma autologous cytolytic T cells by dendritic cell/melanoma cell hybridomas. Cancer Immunol Immunother. 2001;50:307–14.
   PubMed Web of Science ®Google Scholar
• Vasir B, Borges V, Wu Z, Grosman D, Rosenblatt J, Irie M, . Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol. 2005;129:687–700.
   PubMed Web of Science ®Google Scholar
• Chan RC, Xie H, Zhao GP, Xie Y. Dendritomas formed by fusion of mature dendritic cells with allogenic human hepatocellular carcinoma cells activate autologous cytotoxic T lymphocytes. Immunol Lett. 2002;83:101–9.
   PubMedGoogle Scholar
• Sloan AE, Parajuli P. Human autologous dendritic cell–glioma fusions: feasibility and capacity to stimulate T cells with proliferative and cytolytic activity. J Neurooncol. 2003;64: 177–83.
   PubMed Web of Science ®Google Scholar
• Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, . Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin Cancer Res. 2005;11:7891–900.
   PubMedGoogle Scholar
• Koido S, Hara E, Torii A, Homma S, Toyama Y, Kawahara H, . Induction of antigen-specific CD4- and CD8-mediated T-cell responses by fusions of autologous dendritic cells and metastatic colorectal cancer cells. Int J Cancer. 2005 Nov 20;117(4):587–95.
   Google Scholar